U.S. Osteonecrosis Market – Industry Trends and Forecast to 2030

Analyse et perspectives du marché de l'ostéonécrose aux États-Unis

Le nombre croissant de blessures traumatiques au sein de la population américaine devrait stimuler la croissance du marché américain de l'ostéonécrose. L'augmentation des initiatives gouvernementales et du financement de la découverte de médicaments et des programmes de recherche connexes contribue également à la croissance du marché. Les principaux acteurs du marché se concentrent sur divers lancements et approbations de services au cours de cette période cruciale. En outre, l'augmentation des progrès des techniques d'imagerie à des fins de diagnostic de l'ostéonécrose stimule également la croissance du marché au cours de la période prévue.

Le marché américain de l'ostéonécrose devrait croître au cours de l'année de prévision en raison de l'augmentation du nombre d'acteurs sur le marché et de la disponibilité d'appareils diagnostiques et chirurgicaux technologiques avancés. Le développement croissant dans le domaine des techniques avancées devrait encore stimuler la croissance du marché. Cependant, des difficultés telles que les réglementations strictes pour la production et la commercialisation de médicaments de traitement et de dispositifs médicaux pour le diagnostic et la chirurgie devraient freiner la croissance du marché au cours de la période de prévision.

Différentes entreprises prennent des initiatives qui conduisent progressivement à une croissance du marché :

Par exemple,

• En janvier 2021, Stryker a annoncé l'acquisition d'OrthoSensor, un acteur du marché qui applique la technologie numérique et le big data aux prothèses articulaires totales. Cette acquisition permettrait à l'entreprise d'acheter les technologies numériques d'OrthoSensor pour les utiliser dans les technologies de diagnostic et de traitement de l'ostéonécrose.
• En mars 2020, Sciegen Pharmaceuticals a reçu l'approbation ANDA pour les comprimés de naproxène USP 250 mg, 375 mg et 500 mg. Cette approbation contribuera davantage à la croissance du portefeuille de produits de l'entreprise.

Data Bridge Market Research analyse que le marché américain de l'ostéonécrose devrait atteindre la valeur de 843 039,67 milliers USD d'ici 2030, à un TCAC de 5,9 % au cours de la période de prévision.

U.S. Osteonecrosis Market Definition

Osteonecrosis, also referred to as avascular necrosis or aseptic necrosis, is a condition characterized by the death or deterioration of bone tissue due to an inadequate blood supply. It can occur in various bones in the body, but it most commonly affects the hip joint. The compromised blood flow deprives the bone cells of essential oxygen and nutrients, leading to their death and subsequent damage to the affected bone. As a result, the bone structure weakens, becomes less able to withstand normal stress, and may eventually collapse or become deformed. Osteonecrosis can cause pain, limited range of motion, and functional impairment. Common causes of osteonecrosis include trauma, corticosteroid use, excessive alcohol consumption, certain medical conditions, and underlying factors that affect blood circulation. Early diagnosis and appropriate management are essential in preventing further bone damage and preserving joint function. Treatment options for osteonecrosis may include conservative measures to manage symptoms and slow disease progression and surgical interventions to relieve pain and restore joint function.

U.S. Osteonecrosis Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Driver

• Increasing number of traumatic injuries

The increasing number of traumatic injuries in the U.S. is a significant driver for the U.S. osteonecrosis market. Traumatic injuries, caused by various factors such as accidents, sports-related incidents, falls, and workplace injuries, have become more prevalent in recent years. These injuries can profoundly impact bone health, often resulting in fractures, dislocations, and joint instability. When the blood supply to the affected bone is compromised during the injury, it sets the stage for the potential development of osteonecrosis. The damaged blood vessels disrupt the essential supply of oxygen and nutrients to the bone tissue, leading to the death of bone cells. Post-traumatic osteonecrosis is a well-recognized consequence of severe traumatic injuries. Not promptly diagnosed and managed can lead to complications such as joint collapse, chronic pain, and reduced joint function.

A traumatic injury can damage the blood vessels that deliver oxygen and nutrients to the bone tissue. This disruption leads to a decreased or blocked blood flow, resulting in cellular death and the development of osteonecrosis. Additionally, the trauma can increase pressure on the bone or joint, compromising blood flow and causing ischemia. The resulting lack of blood supply and cellular damage can trigger an inflammatory response, further exacerbating the condition. The increasing number of road and sport-related accidents are increasing, leading to an increase in osteonecrosis.

Restraint

• High cost associated with the diagnosis and treatment of osteonecrosis

The advancements in diagnostic techniques and treatment options have improved patient outcomes. Still, the financial burden of managing osteonecrosis remains a significant challenge for patients, healthcare providers, and the healthcare system. The key factors determining the cost of diagnosis and treatment of osteonecrosis include the medical institution or clinic finalized for the procedure, treatment area, complexity, and chosen specialist among others.

Accurate diagnosis of osteonecrosis often requires specialized imaging techniques, such as magnetic resonance imaging (MRI), computed tomography (CT) scans, or bone scans. These diagnostic procedures are expensive, requiring specialized equipment, trained personnel, and interpretation by skilled radiologists. The high cost of these imaging procedures limits access to timely and accurate diagnosis, leading to delayed treatment and potential complications. The cost of the treatment proportionally gets escalated, so the high cost of treatment may hamper the market's demand.

Opportunity

• Advancements in medical technology for osteonecrosis

Advancements in medical technology present significant opportunities in the U.S. osteonecrosis market. These innovations enhance the accuracy of diagnosis, offer regenerative treatment options, enable minimally invasive procedures, facilitate personalized care, and improve patient outcomes. Continued investment in research and development, collaboration between industry and healthcare professionals, and regulatory support for innovative technologies are vital to harness the full potential of medical advancements and drive progress in osteonecrosis. Therefore is expected to act as an opportunity in the market.

Challenge

• Availability of limited treatment options

The absence of therapeutic alternatives in the U.S. osteonecrosis market hampers optimal patient care and outcomes. Osteonecrosis, commonly called avascular necrosis, is a disorder where bone tissue perishes due to inadequate blood flow. Although there are various therapeutic options, the choices are frequently constrained based on osteonecrosis's stage, location, and underlying etiology.

Recent Developments

• In January 2023, Zimmer Biomet announced that it had reached a definitive agreement to acquire Embody, Inc., a privately-held medical device company focused on soft tissue healing, for $155 thousand at closing. The acquisition includes Embody's complete portfolio of collagen-based biointegrative solutions to support healing in the most challenging orthopedic soft tissue injuries – including the TAPESTRY biointegrative implant for tendon healing and TAPESTRY RC, one of the first arthroscopic implant systems for rotator cuff repair. This acquisition will help the company in its product portfolio and business expansion.
• In July 2022, the Haleon Group of Companies announced the completion of the demerger of the Consumer Healthcare business from the GSK Group to form the Haleon Group. This demerges helped the company to take control over the whole business of consumer health and expand it.

U.S. Osteonecrosis Market Scope

The U.S. osteonecrosis market is segmented into ten notable segments based on disease type, type, stages, location, drug type, prescription, gender, age, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.  

Disease Type

• Traumatic
• Non-Traumatic
• Idiopathic

On the basis of disease type, the market is segmented into traumatic, non-traumatic, and idiopathic.

Type

• Diagnosis
• Treatment

On the basis of type, the market is segmented into diagnosis and treatment.

Stages

• Stage 1
• Stage 2
• Stage 3
• Stage 4

On the basis of stages, the market is segmented into stage 1, stage 2, stage3, and stage 4.

Location

• Osteonecrosis of the Hip/ Femoral Head Osteonecrosis
• Osteonecrosis of the Knee
• Osteonecrosis of the Shoulder
• Osteonecrosis of the Talus
• Osteonecrosis of the Lunate
• Osteonecrosis of the Scaphoid
• Others

On the basis of location, the market is segmented into osteonecrosis of hip/femoral head osteonecrosis, osteonecrosis of the knee, osteonecrosis of the shoulder, osteonecrosis of the talus, osteonecrosis of the lunate, osteonecrosis of the scaphoid, and others.

 Drug Type

• Branded
• Generic

On the basis of drug type, the market is segmented into branded and generic.

Prescription

• Over the Counter Drugs
• Prescribed Drugs

On the basis of prescription, the market is segmented into over the counter drugs and prescribed drugs.

Gender

• Male
• Female

On the basis of gender, the market is segmented into male and female.

Age

• Children
• Adult
• Geriatric

On the basis of age, the market is segmented into children, adult, and geriatric.

End User

• Hospitals
• Speciality Clinics
• Orthopedic Clinics
• Ambulatory Centers
• Others

On the basis of end user, the market is segmented into hospitals, specialty clinics, orthopedic clinics, ambulatory centers, and others.

Distribution Channel

• Direct Tender
• Retail Sales

On the basis of distribution channel, the market is segmented into direct tender and retail sales.

U.S. Osteonecrosis Market Analysis/Insights

The U.S. osteonecrosis market is categorized into ten notable segments based on disease type, type, stages, location, drug type, prescription, gender, age, end user, and distribution channel.

The countries covered in this market report U.S.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of U.S. brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and U.S. Osteonecrosis Market Share Analysis

The U.S. osteonecrosis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the U.S. osteonecrosis market.

Some of the major market players operating in the U.S. osteonecrosis market are Sciegen Pharmaceuticals, Almatica Pharma, Dr. Reddy's Laboratories Ltd., Bayer AG, Pfizer Inc., Haleon Group of Companies, Zimmer Biomet, Stryker, Teva Pharmaceuticals USA, Inc. (Subsidiary of Teva Pharmaceutical Industries Ltd.), and Arthrex, Inc. among others.

SKU-70181